Monashee Investment Management LLC Invests $1.16 Million in Vera Therapeutics, Inc. $VERA

Monashee Investment Management LLC purchased a new position in shares of Vera Therapeutics, Inc. (NASDAQ:VERA) in the fourth quarter, according to its most recent filing with the Securities & Exchange Commission. The fund purchased 22,905 shares of the company’s stock, valued at approximately $1,160,000.

A number of other hedge funds and other institutional investors have also modified their holdings of VERA. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. grew its holdings in shares of Vera Therapeutics by 7.7% during the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 30,905 shares of the company’s stock worth $753,000 after buying an additional 2,210 shares in the last quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC grew its holdings in Vera Therapeutics by 22.4% in the first quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 98,013 shares of the company’s stock valued at $2,354,000 after purchasing an additional 17,907 shares during the period. Jane Street Group LLC grew its holdings in Vera Therapeutics by 297.1% in the first quarter. Jane Street Group LLC now owns 41,578 shares of the company’s stock valued at $999,000 after purchasing an additional 62,678 shares during the period. JPMorgan Chase & Co. grew its holdings in Vera Therapeutics by 550.5% in the second quarter. JPMorgan Chase & Co. now owns 310,547 shares of the company’s stock valued at $7,316,000 after purchasing an additional 262,805 shares during the period. Finally, Legal & General Group Plc grew its holdings in Vera Therapeutics by 1.7% in the second quarter. Legal & General Group Plc now owns 50,418 shares of the company’s stock valued at $1,188,000 after purchasing an additional 825 shares during the period. 99.21% of the stock is currently owned by hedge funds and other institutional investors.

Vera Therapeutics Trading Up 6.4%

Shares of VERA stock opened at $33.65 on Friday. The stock has a market cap of $2.42 billion, a price-to-earnings ratio of -6.07 and a beta of 0.93. The company has a quick ratio of 13.64, a current ratio of 13.64 and a debt-to-equity ratio of 0.15. Vera Therapeutics, Inc. has a fifty-two week low of $19.07 and a fifty-two week high of $56.05. The firm’s 50 day moving average price is $37.14 and its two-hundred day moving average price is $41.43.

Vera Therapeutics (NASDAQ:VERA) last posted its earnings results on Thursday, May 7th. The company reported ($1.69) EPS for the quarter, missing analysts’ consensus estimates of ($1.33) by ($0.36). During the same period last year, the business earned ($0.81) EPS. On average, analysts anticipate that Vera Therapeutics, Inc. will post -6.23 EPS for the current year.

Analyst Upgrades and Downgrades

A number of research firms recently issued reports on VERA. HC Wainwright boosted their target price on shares of Vera Therapeutics from $90.00 to $110.00 and gave the company a “buy” rating in a report on Monday, March 2nd. The Goldman Sachs Group reaffirmed a “buy” rating and set a $90.00 price target on shares of Vera Therapeutics in a research report on Tuesday, June 2nd. William Blair reaffirmed an “outperform” rating on shares of Vera Therapeutics in a research report on Tuesday, June 2nd. Jefferies Financial Group reaffirmed a “buy” rating and set a $60.00 price target on shares of Vera Therapeutics in a research report on Tuesday, June 2nd. Finally, Evercore set a $91.00 price target on shares of Vera Therapeutics in a research report on Friday, May 15th. Ten research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $78.00.

Insider Activity at Vera Therapeutics

In other news, CEO Marshall Fordyce sold 22,951 shares of the business’s stock in a transaction on Tuesday, April 14th. The shares were sold at an average price of $44.05, for a total transaction of $1,010,991.55. Following the transaction, the chief executive officer directly owned 235,244 shares of the company’s stock, valued at approximately $10,362,498.20. The trade was a 8.89% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders own 15.90% of the company’s stock.

Vera Therapeutics Company Profile

Vera Therapeutics is a clinical-stage biotechnology company focused on developing novel immunotherapies that harness the body’s own regulatory T cells to treat autoimmune and inflammatory diseases. By leveraging a proprietary protein engineering platform, the company designs Treg-selective cytokine variants intended to restore immune balance and provide targeted, disease-modifying effects. Its pipeline comprises multiple preclinical and clinical candidates aimed at indications characterized by chronic inflammation and autoimmunity.

Founded in 2018 and headquartered in Cambridge, Massachusetts, Vera Therapeutics collaborates with leading academic and research institutions to advance its development programs.